Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (201-210 of 383) with videos related to

Pageof 39
Sort By:
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood Advances|July 19, 2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCTMisha C Tran, Yasmin Hasan, Amy Wang, et al.
Blood|March 21, 2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityJeffrey A Knight, Andrew D Skol, Abhijit Shinde, et al.
Leukemia & Lymphoma|February 26, 2008
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis productsMelinda K Gordon, Dorie Sher, Theodore Karrison, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
The New England Journal of Medicine|June 8, 2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Pageof 39

Showing results (201-210 of 383) with videos related to

Sort By:
Pageof 39
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
The New England Journal of Medicine|March 9, 2017
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaAndreas Hochhaus, Richard A Larson, François Guilhot, et al.
Blood Advances|July 19, 2022
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCTMisha C Tran, Yasmin Hasan, Amy Wang, et al.
Blood|March 21, 2009
Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityJeffrey A Knight, Andrew D Skol, Abhijit Shinde, et al.
Leukemia & Lymphoma|February 26, 2008
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis productsMelinda K Gordon, Dorie Sher, Theodore Karrison, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
The New England Journal of Medicine|June 8, 2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaGiuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Pageof 39